Evelo Biosciences, Inc. (EVLO) financial statements (2020 and earlier)

Company profile

Business Address 620 MEMORIAL DRIVE
CAMBRIDGE, MA 02139
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

9/30/2019
TTM
12/31/2018
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments, including:97148
Cash and cash equivalents9793
Short-term investments 55
Other undisclosed cash, cash equivalents, and short-term investments0(0)
Other undisclosed current assets44
Total current assets:101152
Noncurrent Assets
Property, plant and equipment87
Other noncurrent assets21
Total noncurrent assets:108
TOTAL ASSETS:111160
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities96
Accounts payable12
Accrued liabilities85
Other liabilities03
Total current liabilities:109
Noncurrent Liabilities
Long-term debt and lease obligation2012
Long-term debt, excluding current maturities2012
Liabilities, other than long-term debt11
Deferred rent credit11
Other liabilities00
Total noncurrent liabilities:2114
Total liabilities:3123
Stockholders' equity
Stockholders' equity attributable to parent81137
Common stock00
Additional paid in capital257250
Accumulated other comprehensive loss (0)
Accumulated deficit(176)(113)
Total stockholders' equity:81137
TOTAL LIABILITIES AND EQUITY:111160

Income statement (P&L) ($ in millions)

9/30/2019
TTM
12/31/2018
Operating expenses(80)(58)
Operating loss:(80)(58)
Nonoperating income11
Investment income, nonoperating22
Other nonoperating expense(0)(0)
Interest and debt expense(1)(1)
Loss before gain (loss) on sale of properties:(79)(58)
Other undisclosed net loss(0) 
Net loss:(79)(58)
Other undisclosed net income attributable to parent11
Net loss attributable to parent:(78)(57)
Preferred stock dividends and other adjustments (4)
Net loss available to common stockholders, diluted:(78)(61)

Comprehensive Income ($ in millions)

9/30/2019
TTM
12/31/2018
Net loss:(79)(58)
Comprehensive loss:(79)(58)
Other undisclosed comprehensive income, net of tax, attributable to parent11
Comprehensive loss, net of tax, attributable to parent:(78)(57)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: